An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration
An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration
复制标题
抗血管内皮生长因子治疗多灶性脉络膜炎继发脉络膜新生血管的疗效分析及与湿性年龄相关性黄斑变性的比较
DOI：
10.1631/jzus.b1700535
复制
发表时间：
2018-04
期刊：
影响因子：
--
通讯作者：
Xin Xie
中科院分区：
文献类型：
--
作者：
Lei Feng;Jianghua Hu;Jie Chen;Xin Xie
探讨抗血管内皮生长因子（VEGF）对多灶性脉络膜炎（MFC）和湿性年龄相关性黄斑变性（AMD）继发的中心凹旁脉络膜新生血管（CNV）的影响。研究方法：在这项回顾性比较研究中，将20只患有CNV的独眼分为两组：10例受MFC影响的患者和10例诊断为湿性AMD的患者。他们都接受了局部玻璃体内（IVT）注射雷珠单抗，随访6个月。根据提示活跃新生血管形成的结果进行再治疗注射。抗VEGF治疗后，两组中心凹附近CNV病变明显改善，平均黄斑厚度降低（P<0.05）。MFC患者的平均注射次数为1.6次，而湿性AMD患者的平均注射次数为3次（Z=-2.844，P=0.009）。MFC患者抗VEGF治疗后最佳矫正视力较治疗前明显提高（P<0.05），而湿性AMD患者抗VEGF治疗6个月后最佳矫正视力与治疗前比较差异无统计学意义（P>0.05）。IVT雷珠单抗治疗继发于MFC和湿性AMD的中心凹旁CNV的临床结局良好，但在6个月的观察期内，MFC中使用的平均注射次数少于湿性AMD中使用的注射次数。与湿性AMD组相比，MFC组在6个月时视力明显提高。
To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). Methods: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy (P<0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients (Z=−2.844, P=0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy (P<0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later (P>0.05). IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
登录
查看更多内容
与葡萄膜炎相关的脉络膜新血管形成：从发病机理到治疗。
影响因子：
1.9
作者：
D'Ambrosio E;Tortorella P;Iannetti L
通讯作者：
Iannetti L
影响因子：
0.8
作者：
Y. Perentes;C. Chan;E. Bovey;S. Uffer;C. Herbort
通讯作者：
Y. Perentes;C. Chan;E. Bovey;S. Uffer;C. Herbort
DOI：
--
发表时间：
2016
期刊：
Romanian Journal of Ophthalmology
影响因子：
--
作者：
Malciolu Radu Alexandru;Nica Maria Alexandra
通讯作者：
Malciolu Radu Alexandru;Nica Maria Alexandra
影响因子：
4.2
作者：
Haen, Sebastian P.;Spaide, Richard F.
通讯作者：
Spaide, Richard F.
影响因子：
3.4
作者：
Julian, Karina;Terrada, Celine;Bodaghi, Bahram
通讯作者：
Bodaghi, Bahram